Roche’s Anderson wants industry to keep its foot on the gas for infectious disease, post-pandemic: a BioCentury audio interview
Roche Pharma CEO Anderson optimistic about improving drug development broadly, but stakeholders will need to keep pushing to solve antimicrobial resistance
There will be no turning back to business as usual for drug developers and regulators after COVID-19, according to Bill Anderson, CEO of Roche Pharmaceuticals. But while he’s optimistic about speeding up timelines and changing clinical trial practices, he says industry must keep pushing governments to help solve antimicrobial resistance.
In a Back to School audio interview, Anderson predicted that accelerated interactions with regulators and steps drug companies have taken to speed drug development will endure and lead to both increased throughput of follow-on products and lower prices. This conversation was one of a series of interviews with key industry leaders for BioCentury’s 2020 Back to School package (see Cover Story: “The Imperative of COVID-19”)...